Dasiglucagon Well Tolerated for Severe Hypoglycemia

Share this content:
Dasiglucagon Well Tolerated for Severe Hypoglycemia
Dasiglucagon Well Tolerated for Severe Hypoglycemia

WEDNESDAY, Jan. 3, 2018 (HealthDay News) -- Dasiglucagon is well tolerated and is associated with an early pharmacodynamic response similar to that of GlucaGen for severe hypoglycemia, according to a study published online Dec. 22 in Diabetes Care.

Ulrike Hövelmann, M.D., from Profil in Neuss, Germany, and colleagues compared the pharmacokinetic and pharmacodynamic characteristics, safety, and tolerability of different doses of the soluble glucagon analog dasiglucagon with approved pediatric and full doses of GlucaGen. A total of 58 patients with type 1 diabetes were randomized to receive single subcutaneous injections of 0.1, 0.3, 0.6, or 1 mg dasiglucagon or 0.5 or 1 mg GlucaGen in a state of intravenous insulin infusion-induced hypoglycemia.

The researchers observed a dose-dependent and rapid increase in plasma concentrations with dasiglucagon, reaching a maximum at about 35 minutes and with a half-life of about 0.5 hours. There was a rapid increase in plasma glucose with dasiglucagon by ≥20 mg/dL to ≥70 mg/dL, similar to GlucaGen, but greater and longer-lasting. These end points were reached by all patients on both treatments within 30 minutes. Treatments were well tolerated; the most frequent adverse event was nausea, which occurred at a similar rate in both groups.

"Dasiglucagon has the potential to become an effective and reliable rescue treatment for severe hypoglycemia in a ready-to-use pen," the authors write.

Several authors disclosed financial ties to pharmaceutical companies, including Zealand Pharma, which manufactures dasiglucagon and funded the study.

Abstract/Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease


Sign up for myCME e-newsletters


More in Home

Lap Sleeve Gastrectomy, RYGB Equally Effective in Weight Loss

Lap Sleeve Gastrectomy, RYGB Equally Effective in Weight ...

Studies show no significant difference in BMI loss at five years between these laparoscopic procedures

ASCO: Liquid Biopsy Accurate for Detecting Colorectal Cancer

ASCO: Liquid Biopsy Accurate for Detecting Colorectal Cancer

Novel assay to detect circulating tumor cells has high sensitivity, specificity for precancerous lesions

Speech Outcomes Can Be Predicted After Cochlear Implant

Speech Outcomes Can Be Predicted After Cochlear Implant

Regions of brain that were unaffected by auditory deprivation provide most precise prediction results

is free, fast, and customized just for you!

Already a member?

Sign In Now »